Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record.

The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers

Sanderink, Ger‐Jan, Le Liboux, Aimé, Jariwala, Navin, Harding, Neasa, Ozoux, Marie‐Laure, Shukla, Umesh, Montay, Guy, Boutouyrie, Bruno, Miro, Adelaida · 2002 · Clinical Pharmacology & Therapeutics

Abstract

Objectives: The objective of this study was to compare the pharmacokinetics of the low‐molecular‐weight heparin enoxaparin in obese and nonobese volunteers, by means of two administration regimens. Methods: Enoxaparin was administered subcutaneously (1.5 mg/kg once daily for 4 days) and in a single 6‐hour infusion (1.5 mg/kg) to 24 obese volunteers and 24 age‐, sex‐, and height‐matched nonobese volunteers in a randomized, open‐label, 2‐way crossover design. Blood plasma was assessed for anti‐Xa and anti‐IIa activity and activated partial thromboplastin time. Results: After subcutaneous administration, steady‐state exposure was achieved after the second dose in nonobese volunteers and after the third dose in obese volunteers. Time to maximum anti‐Xa activity was 1 hour longer in obese volunteers, but maximum anti‐Xa activity was similar in both groups. For anti‐Xa activity, exposure at steady‐state was 16% higher in obese volunteers than in nonobese volunteers (90% confidence interval, 108%‐125%). After intravenous infusion, total body clearance and volume of distribution at steady state were higher in obese volunteers than in nonobese volunteers, but when adjusted for weight, these values were about 10% lower in obese volunteers. Anti‐IIa activity after subcutaneous administration did not differ significantly between obese and nonobese volunteers. Pharmacodynamic analysis of activated partial thromboplastin time showed similar results in obese and nonobese volunteers after both intravenous and subcutaneous administration. No deaths or serious adverse events occurred during the study. Conclusions: Enoxaparin was well tolerated when administered subcutaneously or intravenously, and there appears to be no need to modify the currently recommended dose for obese volunteers. Clinical Pharmacology & Therapeutics (2002) 72, 308–318; doi: 10.1067/mcp.2002.127114

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1067/mcp.2002.127114

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 186

Metadata

Authors
Sanderink, G., Le Liboux, A., Jariwala, N., Harding, N., Ozoux, M., Shukla, U., Montay, G., Boutouyrie, B., & Miro, A.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2002-09
Volume
72
Issue
3
Pages
308-318
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
OpenAlex
W2169845753
Cited by
186
References
0
FWCI
7.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. https://app.cochat.ai/papers/10.1067/mcp.2002.127114
The paper
Sanderink, G., Le Liboux, A., Jariwala, N., Harding, N., Ozoux, M., Shukla, U., Montay, G., Boutouyrie, B., & Miro, A. (2002). The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clinical Pharmacology & Therapeutics. https://doi.org/10.1067/mcp.2002.127114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.